Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://cupitt.com.au
Are you over 18 and want to see adult content?
A complete backup of https://homeorganizer.pro
Are you over 18 and want to see adult content?
A complete backup of https://koe.org.gr
Are you over 18 and want to see adult content?
A complete backup of https://cleanup.expert
Are you over 18 and want to see adult content?
A complete backup of https://clubshop.com
Are you over 18 and want to see adult content?
A complete backup of https://emjreviews.com
Are you over 18 and want to see adult content?
A complete backup of https://viar360.com
Are you over 18 and want to see adult content?
A complete backup of https://playr.gg
Are you over 18 and want to see adult content?
A complete backup of https://aebrus.ru
Are you over 18 and want to see adult content?
A complete backup of https://fbwhatsapquotes.com
Are you over 18 and want to see adult content?
A complete backup of https://goldengoose-ggdb.com
Are you over 18 and want to see adult content?
A complete backup of https://alarab.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of palmspringspropertymanagement.com
Are you over 18 and want to see adult content?
A complete backup of lagudownload.net
Are you over 18 and want to see adult content?
A complete backup of visitblackpool.com
Are you over 18 and want to see adult content?
A complete backup of shalimar-flensburg.de
Are you over 18 and want to see adult content?
A complete backup of journeyprice.co.uk
Are you over 18 and want to see adult content?
Text
trial in
LAG-3 DRUGS TAKE CENTRE STAGE AT ASCO, SHOWING POTENTIAL LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year’s ASCO conference after trial results showed their EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU regulators have started a review to assess reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from Pfizer/BioNTech, AstraZeneca and Moderna. RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EMA PANEL PROBES HEART INFLAMMATION WITH PFIZER/BIONTECH A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND A smartphone app that uses artificial intelligence to assess the sound of coughing has been launched in the UK, and according to its developer could be an early warning system for COVID-19 and ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3trial in
LAG-3 DRUGS TAKE CENTRE STAGE AT ASCO, SHOWING POTENTIAL LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year’s ASCO conference after trial results showed their EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU regulators have started a review to assess reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from Pfizer/BioNTech, AstraZeneca and Moderna. RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for future changes BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EMA PANEL PROBES HEART INFLAMMATION WITH PFIZER/BIONTECH A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND A smartphone app that uses artificial intelligence to assess the sound of coughing has been launched in the UK, and according to its developer could be an early warning system for COVID-19 and ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PRICING, PROFITS AND PROGRESS: PHARMA’S POST-COVID 1 day ago · As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn explores pharma’s priorities on pricing, profits and progress post-Covid. It goes without saying thatif
KEEPING CLINICAL TRIAL DATA SAFE 6 hours ago · The development of vaccines for COVID-19 has been a masterclass in effective collaboration and applied digitisation in healthcare. However the OCUGEN GETS A BLACK EYE AS FDA DENIES EMERGENCY OK FOR 9 hours ago · Ocugen is the first company to be affected by the FDA’s recent decision to raise the bar on emergency use authorisations for COVID-19 medicines, and will have to file for fullapproval of its
EHA21: SANOFI BUILDS CASE FOR RARE DISEASE DRUG SUTIMLIMAB 8 hours ago · Sanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) were dashed by the FDA, but new phase 3 TRIAL FINDS ORION DIGITAL THERAPEUTIC HELPS CHRONIC PAIN 9 hours ago · A digital therapeutic aimed at people with chronic lower back pain based on virtual reality (VR) has shown encouraging results in a clinical trial, helping patients manage the fear ofmovement
EHA21: NOVARTIS TRUMPETS IPTACOPAN AS ORAL ALTERNATIVE TO The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the STUDY LINKS ASTRAZENECA COVID-19 SHOT TO BLEEDING DISORDER 1 day ago · Scottish study suggests possible link between the AstraZeneca covid-19 vaccine with autoimmune disorder idiopathic thrombocytopenic purpura (ITP), but experts say the risk is BMS WILL FILE FOR EARLIER-LINE USE OF BREYANZI IN LYMPHOMA 9 hours ago · Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtakerival
AND THEN THERE WERE THREE: ANOTHER FDA ADCOMM MEMBER QUITS 8 hours ago · The fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest. Thelatest to
PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3trial in
RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3trial in
RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PRICING, PROFITS AND PROGRESS: PHARMA’S POST-COVID 17 hours ago · As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn explores pharma’s priorities onpricing, profits
MERCK NABS $1.2 BILLION ORDER FOR ORAL COVID ANTIVIRAL 1 day ago · The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for STUDY LINKS ASTRAZENECA COVID-19 SHOT TO BLEEDING DISORDER 20 hours ago · Scottish study suggests possible link between the AstraZeneca covid-19 vaccine with autoimmune disorder idiopathic thrombocytopenic purpura (ITP), but experts say the risk is US ORDERS 500M PFIZER/BIONTECH COVID JABS FOR DEVELOPING 17 hours ago · White House orders 500m doses of the Pfizer and BioNTech COVID-19 vaccine for donation to lower-income countries, with a phased delivery due to start in August PHARMACEUTICAL MANUFACTURING AND PACKAGING CONGRESS 2021 Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2021) will be held on the 28th – 29th of June, 2021 at the BGS online platform. CIOs and directors of pharmaceutical companies and DOUBLE RESIGNATION OVER ADUHELM APPROVAL DEPLETES FDA'S 18 hours ago · Two members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s disease drug Aduhelm despite an overwhelming voteagainst doing so
NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the HOW COVID-19 IS CHANGING THE SALES MODEL How COVID-19 is changing the sales model. George Underwood. May 20, 2020. The COVID-19 pandemic means that reps can no longer speakface-to
FDA CLEARS PFIZER'S PREVNAR 20 FOR ADULTS, AS MERCK RIVAL 1 day ago · Pfizer bags its first approval in the US for Prevnar 20, its new 20-valent pneumococcal conjugate vaccine, a few weeks ahead of an FDA decision on Merck's rival V114 BAYER'S TWO-PRONGED CELL/GENE THERAPY ASSAULT ON PARKINSON 1 day ago · Bayer's cell and gene therapy candidates for Parkinson's, acquired via bolt-on deals with BlueRock and AskBio, have reached the clinical testing stage PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3trial in
RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3trial in
RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn STUDY LINKS ASTRAZENECA COVID-19 SHOT TO BLEEDING DISORDER 13 hours ago · Scottish study suggests possible link between the AstraZeneca covid-19 vaccine with autoimmune disorder idiopathic thrombocytopenic purpura (ITP), but experts say the risk is MERCK NABS $1.2 BILLION ORDER FOR ORAL COVID ANTIVIRAL 1 day ago · The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the ROIVANT SPINOUT DATAVANT MERGES WITH CIOX TO FORM $7BN Merger between Datavant and Ciox Health will create a digital health and patient data giant in the US valued at $7bn, with a national network generating annual revenues of $700m ENSURING ACCESSIBILITY: CROSSING THE DIGITAL DIVIDE IN 1 day ago · “It is arguably one of the most important issues of the 21st century, and the pandemic has merely amplified the need for a more digitally inclusive society” FDA CLEARS PFIZER'S PREVNAR 20 FOR ADULTS, AS MERCK RIVAL 1 day ago · Pfizer bags its first approval in the US for Prevnar 20, its new 20-valent pneumococcal conjugate vaccine, a few weeks ahead of an FDA decision on Merck's rival V114 HOW COVID-19 IS CHANGING THE SALES MODEL How COVID-19 is changing the sales model. George Underwood. May 20, 2020. The COVID-19 pandemic means that reps can no longer speakface-to
BAYER'S TWO-PRONGED CELL/GENE THERAPY ASSAULT ON PARKINSON 1 day ago · Bayer's cell and gene therapy candidates for Parkinson's, acquired via bolt-on deals with BlueRock and AskBio, have reached the clinical testing stage ADUHELM APPROVAL COULD SIGNAL NEW ERA FOR CNS DRUGS 1 day ago · The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry asa
WELCOMING ANALYTICS-DRIVEN DIGITAL MARKETING AGENCY At Fishawack Health, we are always seeking opportunities to enhance our capabilities and help our life science clients navigate the new, dynamically changing healthcare environment. As part of PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Novartis halts three trials of Beovu eye drug on safety concerns. Phil Taylor. June 1, 2021. Prospects for Novartis’ ophthalmology drug Beovu have taken another dive RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Prospects for Novartis’ ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3trial in
RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn STUDY LINKS ASTRAZENECA COVID-19 SHOT TO BLEEDING DISORDER Scottish study suggests possible link between the AstraZeneca covid-19 vaccine with autoimmune disorder idiopathic thrombocytopenic purpura (ITP), but experts say the risk is MERCK NABS $1.2 BILLION ORDER FOR ORAL COVID ANTIVIRAL The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the ROIVANT SPINOUT DATAVANT MERGES WITH CIOX TO FORM $7BN Merger between Datavant and Ciox Health will create a digital health and patient data giant in the US valued at $7bn, with a national network generating annual revenues of $700m ENSURING ACCESSIBILITY: CROSSING THE DIGITAL DIVIDE IN 1 day ago · “It is arguably one of the most important issues of the 21st century, and the pandemic has merely amplified the need for a more digitally inclusive society” FDA CLEARS PFIZER'S PREVNAR 20 FOR ADULTS, AS MERCK RIVAL 1 day ago · Pfizer bags its first approval in the US for Prevnar 20, its new 20-valent pneumococcal conjugate vaccine, a few weeks ahead of an FDA decision on Merck's rival V114 HOW COVID-19 IS CHANGING THE SALES MODEL How COVID-19 is changing the sales model. George Underwood. May 20, 2020. The COVID-19 pandemic means that reps can no longer speakface-to
BAYER'S TWO-PRONGED CELL/GENE THERAPY ASSAULT ON PARKINSON 1 day ago · Bayer's cell and gene therapy candidates for Parkinson's, acquired via bolt-on deals with BlueRock and AskBio, have reached the clinical testing stage ADUHELM APPROVAL COULD SIGNAL NEW ERA FOR CNS DRUGS 1 day ago · The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry asa
WELCOMING ANALYTICS-DRIVEN DIGITAL MARKETING AGENCY At Fishawack Health, we are always seeking opportunities to enhance our capabilities and help our life science clients navigate the new, dynamically changing healthcare environment. As part of PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Novartis halts three trials of Beovu eye drug on safety concerns. Phil Taylor. June 1, 2021. Prospects for Novartis’ ophthalmology drug Beovu have taken another dive RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. NICE 'NO' TO ROCHE'S RISDIPLAM FOR SMA NOT UNEXPECTED NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as NOVARTIS HALTS THREE TRIALS OF BEOVU EYE DRUG ON SAFETY Novartis halts three trials of Beovu eye drug on safety concerns. Phil Taylor. June 1, 2021. Prospects for Novartis’ ophthalmology drug Beovu have taken another dive RESEARCH PREDICTS THE POST-COVID LANDSCAPE FOR HCP ENGAGEMENT Research predicts the post-COVID landscape for HCP engagement. May 12, 2021. IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTURE Customer engagement and pharma’s field force future. How healthcare professionals prefer to engage with pharma companies has been changing COVID COUGH APP HYFE LAUNCHES IN UK AND IRELAND COVID cough app Hyfe launches in UK and Ireland. Phil Taylor. March 9, 2021. A smartphone app that uses artificial intelligence to assess the ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESHAUTHOR:RICHARD STAINES
Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn STUDY LINKS ASTRAZENECA COVID-19 SHOT TO BLEEDING DISORDER Scottish study suggests possible link between the AstraZeneca covid-19 vaccine with autoimmune disorder idiopathic thrombocytopenic purpura (ITP), but experts say the risk is MERCK NABS $1.2 BILLION ORDER FOR ORAL COVID ANTIVIRAL The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral therapy molnupiravir for COVID-19, assuming it gets approved for NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the ROIVANT SPINOUT DATAVANT MERGES WITH CIOX TO FORM $7BN Merger between Datavant and Ciox Health will create a digital health and patient data giant in the US valued at $7bn, with a national network generating annual revenues of $700m ENSURING ACCESSIBILITY: CROSSING THE DIGITAL DIVIDE IN 21 hours ago · “It is arguably one of the most important issues of the 21st century, and the pandemic has merely amplified the need for a more digitally inclusive society” FDA CLEARS PFIZER'S PREVNAR 20 FOR ADULTS, AS MERCK RIVAL 23 hours ago · Pfizer bags its first approval in the US for Prevnar 20, its new 20-valent pneumococcal conjugate vaccine, a few weeks ahead of an FDA decision on Merck's rival V114 HOW COVID-19 IS CHANGING THE SALES MODEL How COVID-19 is changing the sales model. George Underwood. May 20, 2020. The COVID-19 pandemic means that reps can no longer speakface-to
BAYER'S TWO-PRONGED CELL/GENE THERAPY ASSAULT ON PARKINSON 23 hours ago · Bayer's cell and gene therapy candidates for Parkinson's, acquired via bolt-on deals with BlueRock and AskBio, have reached the clinical testing stage ADUHELM APPROVAL COULD SIGNAL NEW ERA FOR CNS DRUGS 22 hours ago · The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications forthe industry as a
WELCOMING ANALYTICS-DRIVEN DIGITAL MARKETING AGENCY At Fishawack Health, we are always seeking opportunities to enhance our capabilities and help our life science clients navigate the new, dynamically changing healthcare environment. As part of PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTSAUTHOR:RICHARD STAINES
EU regulators have started a review to assess reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from Pfizer/BioNTech, AstraZeneca and Moderna. BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEAR Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. THE BIGGEST CHALLENGES FACING RARE DISEASE PHARMA As Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers and ask whether the future is bright or bleak for these difficult conditions. 2021 - UK MARKET ACCESS PROSPECTS - PHARMAPHORUMSTOCK MARKET PROSPECTSMARKET PROSPECT RATIOSPROSPECT MARKET BROOKLYNPROSPECTS PLUS POSTCARDSSTOCK MARKET IF TRUMP LOSES 2020 was a big year for market access initiatives in the UK, many of which are only just starting, and their impact will come through in 2021 and beyond. Looking back at ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESH Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn HUMIRA DEVELOPER WINTER AMONG NOBEL CHEMISTRY PRIZE WINNERSAMERICAN NOBEL PRIZE WINNERSLATEST NOBEL PRIZE WINNERSNEW NOBEL PRIZE WINNERSNOBEL PRIZE FACTSNOBEL PRIZE WINNERS IN CHEMISTRYPERSON WITHMOST NOBEL PRIZES
A scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, was among a trio who received this year’s Nobel Prize in Chemistry. PRALUENT NOT WORTH THE PRICE, FINDS STUDY Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed. LATECOMER LILLY THROWS CASH AT INNOVENT PD-1 PARTNERSHIP Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be launched at a XTANDI TAKES FIGHT TO PROSTATE CANCER RIVALS WITH SURVIVAL Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend off growing competition in themarket.
PHARMA NEWS, VIEWS AND ANALYSIS Pharma news, views and analysis of healthcare in a rapidly changing world. pharmaphorum reports all the latest information. BMS' DEUCRAVACITINIB PSORIASIS PILL COULD LAUNCH NEXT YEARAUTHOR:RICHARD STAINES
April 26, 2021. Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease. The EU PROBES LOW PLATELET SAFETY SIGNAL WITH COVID-19 SHOTS EU probes low platelet safety signal with COVID-19 shots. Richard Staines. March 12, 2021. EU regulators are reviewing reports of low blood platelets in patients who received any of the three THE BIGGEST CHALLENGES FACING RARE DISEASE PHARMA The challenges are manifold, covering areas as broad as economics, research and disease awareness. “There is an inherent economical challenge with rare diseases,” Dr Ron Jortner tells 2021 - UK MARKET ACCESS PROSPECTS - PHARMAPHORUMSTOCK MARKET PROSPECTSMARKET PROSPECT RATIOSPROSPECT MARKET BROOKLYNPROSPECTS PLUS POSTCARDSSTOCK MARKET IF TRUMP LOSES 2020 was a big year for market access initiatives in the UK, many of which are only just starting, and their impact will come through in 2021 and beyond. Looking back at KOL MAPPING AND VALIDATION KOL validation starts with the correct assumption that you know your KOLs well already, and many of our clients do. All you need is an unbiased sense-check to quickly and efficiently validate your ACTIVIST INVESTOR ELLIOTT BUILDS STAKE IN GSK AFTER FRESH Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to turn HUMIRA DEVELOPER WINTER AMONG NOBEL CHEMISTRY PRIZE WINNERSAMERICAN NOBEL PRIZE WINNERSLATEST NOBEL PRIZE WINNERSNEW NOBEL PRIZE WINNERSNOBEL PRIZE FACTSNOBEL PRIZE WINNERS IN CHEMISTRYPERSON WITHMOST NOBEL PRIZES
A scientist who pioneered the technology used to discover the biggest selling drug in the world, AbbVie’s Humira, was among a trio who received this year’s Nobel Prize in Chemistry. XTANDI TAKES FIGHT TO PROSTATE CANCER RIVALS WITH SURVIVAL Xtandi takes fight to prostate cancer rivals with survival data. Phil Taylor. February 12, 2020. Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it PRALUENT NOT WORTH THE PRICE, FINDS STUDY Praluent not worth the price, finds study. Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study EXPERTS DISCUSS THE FIELD FORCE’S CUSTOMER-CENTRIC FUTURE 20 hours ago · The ways in which HCPs prefer to engage with pharma has been changing for quite some time, and the digital transformation brought by COVID has dramatically accelerated that. In a recent NOT JUST COVID-19 VACCINES: 5 THINGS THAT CAUSE BLOOD CLOTS Reports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the rarity of incidences from vaccination, myGP explores the WHAT HCPS THINK ABOUT BLOOD CLOTS LINKED TO COVID-19 In the latest edition of What HCPs Think, CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clotslinked to
DIGITAL FABRIC COULD BE USED TO MEASURE HEALTH DATA 20 hours ago · The fibre was created by placing hundreds of square silicon microscale digital chips into a preform that was then used to create a flexible, polymer thread, thin and flexible enough to beworked
JUBILATION FOR BIOGEN, EISAI AS FDA SAYS 'YES' TO ADUCANUMAB Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab as thefirst-ever
ASCO21: GILEAD SETS UP FIRST FDA OKAY FOR ADULT ALL WITH 20 hours ago · Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences’ Kite subsidiary is now looming in the rear view mirror J&J BACKS OUT OF $1.6BN BLOOD CANCER ANTIBODY ALLIANCE 19 hours ago · Disappointment for Belgian biotech Argenx as J&J ducks out of their $1.6bn alliance on acute myeloid leukaemia antibody cusatuzumab, citing "evolving standard of care" for the blood cancer GSK AND MEDICAGO'S PLANT-BASED COVID SHOT HEADS INTO PHASE 3 GSK be hoping that a partnership with the Canadian biotech Medicago will run smoothly as a trial of the plant-based vaccine enters itslate stage.
SCOTLAND BACKS RARE BLOOD CANCER DRUG POTELIGEO REJECTED A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Poteligeo for two rare blood cancers, a TIME FOR A NICE CHANGE The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of how the worldhas
Menu Close
__
SEARCH
ADVANCED SEARCH
Free search Exact search Search: Category: Select CategoryEventsNewsPartner contentVideoViews and analysisWebinarsWhite Papers Range: Select rangeLast weekLast monthLast quarterLast yearSubscribe Sign In
Why register?
__ __
__
__
__
__
* Home
* Views & analysis
* Digital Debates
* White Papers
* Podcasts & Videos
* Partner content
* News
* Events
* Find an event
* Live event coverage* Deep Dive
* Sales and marketing* News
* Views & Analysis
* Debates & Insight
* Partner Content
* Digital
* News
* Views & Analysis
* Debates & Insight
* Partner Content
* Market Access
* News
* Views & Analysis
* Debates & Insight
* Partner Content
* Oncology
* News
* Views & Analysis
* Debates & Insight
* Partner Content
* Patients
* News
* Views & Analysis
* Debates & Insight
* Partner Content
* R&D
* News
* Views & Analysis
* Debates & Insight
* Partner Content
* Spotlight On
* Disease spotlight: DMD * Disease spotlight: LHON * Behavioural science in pharma * Understanding HCPs * The Future of Generics* Advertise
Search
Search
Close
TRENDING
* Value-based healthcare: Pandemic learnings and future musings * ASCO21: Lynparza aces adjuvant breast cancer therapy trial * Bayer props up sagging radionuclide business with Noria acquisition * ASCO21: Novartis’ prostate cancer radiotherapy extends survival * The Bloc hires Stuart Goldstein as COO*
in News
ASCO21: LYNPARZA ACES ADJUVANT BREAST CANCER THERAPY TRIALJune 4, 2021 Share
X
ASCO21: Lynparza aces adjuvant breast cancer therapy trial https://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/*
in News
BAYER PROPS UP SAGGING RADIONUCLIDE BUSINESS WITH NORIA ACQUISITIONJune 4, 2021 Share
X
Bayer props up sagging radionuclide business with Noria acquisition https://pharmaphorum.com/news/bayer-props-up-sagging-radionuclide-business-with-noria-acquisition/*
in Views and analysis VALUE-BASED HEALTHCARE: PANDEMIC LEARNINGS AND FUTURE MUSINGSJune 4, 2021 Share
X
Value-based healthcare: Pandemic learnings and future musings https://pharmaphorum.com/views-and-analysis/value-based-healthcare-pandemic-learnings-and-future-musings/*
in Views & Analysis
TIME FOR A NICE CHANGEJune 3, 2021 Share
X
Time for a NICE change https://deep-dive.pharmaphorum.com/magazine/market-access-2021/time-for-a-nice-change/»
LATEST NEWS
ASCO21: NOVARTIS’ PROSTATE CANCER RADIOTHERAPY EXTENDS SURVIVAL Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped menShare
X
ASCO21: Novartis’ prostate cancer radiotherapy extends survival https://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/ THE BLOC HIRES STUART GOLDSTEIN AS COO Stuart Goldstein has been hired as the chief operating officer at New-York-based healthcare creative agency The Bloc. InShare
X
The Bloc hires Stuart Goldstein as COO https://pharmaphorum.com/news/the-bloc-hires-stuart-goldstein-as-coo/ FDA GRANTS SWIFT APPROVAL TO COGNOA’S DIGITAL DEVICE FOR AUTISMDIAGNOSIS
The FDA has approved a digital device developed by Cognoa that can be used to diagnose autism spectrumShare
X
FDA grants swift approval to Cognoa’s digital device for autismdiagnosis
https://pharmaphorum.com/news/fda-grants-swift-approval-to-cognoas-digital-device-for-autism-diagnosis/See all
VIEWS & ANALYSIS
CHANGING FOCUS TO CACHEXIA MAY BE KEY TO IMPROVED CANCER OUTCOMES Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. PhysicianShare
X
Changing focus to cachexia may be key to improved cancer outcomes https://pharmaphorum.com/views-analysis-oncology/changing-focus-to-cachexia-may-be-key-to-improved-cancer-outcomes/ BIO-EUROPE SPRING DIGITAL: BIG DATA AND AI PANEL DISCUSSION The combination of big data and artificial intelligence/machine learning is a powerful one and nowhere more so thanShare
X
BIO-Europe Spring Digital: Big data and AI panel discussion https://pharmaphorum.com/digital/bio-europe-spring-digital-big-data-and-ai-applications-in-the-real-world/ WHAT HCPS THINK ABOUT BLOOD CLOTS LINKED TO COVID-19 VACCINES In the latest edition of What HCPs Think, CREATION.co’s Laura Marsh looks at what healthcare professionals are saying aboutShare
X
What HCPs think about blood clots linked to COVID-19 vaccines https://pharmaphorum.com/views-and-analysis/what-hcps-think-about-blood-clots-linked-to-covid-19-vaccines/See all
DEEP DIVE MAGAZINE
TIME FOR A NICE CHANGE The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical andShare
X
Time for a NICE change https://deep-dive.pharmaphorum.com/magazine/market-access-2021/time-for-a-nice-change/ RETHINKING ACCESS BARRIERS TO INNOVATION Market access issues don’t stop once a product has passed HTA – and this is especially true forShare
X
Rethinking access barriers to innovation https://deep-dive.pharmaphorum.com/magazine/market-access-2021/rethinking-access-barriers-to-innovation/ AI MEETS RWE: THE FUTURE OF DRUG ASSESSMENT? Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amountsShare
X
AI meets RWE: The future of drug assessment? https://pharmaphorum.com/views-analysis-market-access/ai-meets-rwe-the-future-of-drug-assessment/See all
WEBINARS
USING AI TO MAKE A BIG IMPACT FOR EMERGING AND MID-SIZED BIOPHARMACOMPANIES
Share
X
Using AI to make a big impact for emerging and mid-sized biopharmacompanies
https://pharmaphorum.com/webinars/using-ai-to-make-a-big-impact-for-emerging-and-mid-sized-biopharma-companies/ THE DIGITAL TRANSFORMATION OF PHARMA’S PHYSICIAN ENGAGEMENTSTRATEGIES
Share
X
The digital transformation of pharma’s physician engagementstrategies
https://pharmaphorum.com/webinars/digital-transformation-pharma-engagement-p360/ CUSTOMER ENGAGEMENT AND PHARMA’S FIELD FORCE FUTUREShare
X
Customer engagement and pharma’s field force future https://pharmaphorum.com/webinars/axtria-customer-engagement-pharmas-field-force-future-digital-transformation/See all
WHITE PAPERS
4 WAYS TO EMBED DATA-DRIVEN BEST PRACTICE IN PHARMA HCP COMMUNICATIONS Virtual communications between sales reps and HCPs jumped significantly during 2020, making it more important than ever forShare
X
4 ways to embed data-driven best practice in pharma HCP communications https://pharmaphorum.com/whitepapers/4-ways-to-embed-data-driven-best-practice-in-pharma-hcp-communications/ A DIGITAL HEALTH ROADMAP FOR PHARMA, MEDICAL DEVICES AND INSURANCETECH
COVID-19 has massively accelerated the uptake of digital health technology across the whole ecosystem, with important implications forShare
X
A digital health roadmap for pharma, medical devices and insurancetech
https://pharmaphorum.com/whitepapers/digital-health-roadmap-pharma-medical-devices-insurance/ PLUGGING MODULAR CONTENT INTO PHARMA’S OMNICHANNEL STRATEGIES 86% of respondents to a recent Veeva survey of pharma and biotech professionals said they are creating aShare
X
Plugging modular content into pharma’s omnichannel strategies https://pharmaphorum.com/whitepapers/plugging-modular-content-into-pharmas-omnichannel-strategies/See all
VIDEO
BIO-EUROPE SPRING DIGITAL: BIG DATA AND AI PANEL DISCUSSIONShare
X
BIO-Europe Spring Digital: Big data and AI panel discussion https://pharmaphorum.com/digital/bio-europe-spring-digital-big-data-and-ai-applications-in-the-real-world/ BIO-EUROPE SPRING DIGITAL: NERIDA SCOTT, J&J’S EMEA INNOVATION HEADShare
X
BIO-Europe Spring Digital: Nerida Scott, J&J’s EMEA Innovation Head https://pharmaphorum.com/video/nerida-scott-interview-with-jjs-emea-innovation-head/ PHARMA’S POST-COVID PROSPECTS: THE PHARMAPHORUM PODCASTShare
X
Pharma’s post-COVID prospects: the pharmaphorum podcast https://pharmaphorum.com/podcast/pharma-post-covid-prospects-accenture/See all
PARTNER CONTENT
PRESS RELEASES
G7 HEALTH SUMMIT HIGHLIGHTS OXFORDSHIRE’S THRIVING LIFE SCIENCESSECTOR
Share
X
G7 health summit highlights Oxfordshire’s thriving life sciencessector
https://pharmaphorum.com/partner-content/press-releases/g7-health-summit-highlights-oxfordshires-thriving-life-sciences-sector/ COUCH HEALTH FINDS REASONS BEHIND UNDERREPRESENTATION OF MINORITIES INUS CLINICAL TRIALS
Share
X
COUCH Health Finds Reasons Behind Underrepresentation of Minorities inUS Clinical Trials
https://pharmaphorum.com/partner-content/couch-health-finds-reasons-behind-underrepresentation-of-minorities-in-us-clinical-trials/ DIGITAL KOLS FOR DIGITAL ENGAGEMENTShare
X
Digital KOLs For Digital Engagement https://pharmaphorum.com/partner-content/digital-kols-for-digital-engagement/ FORMEDIX EXPEDITES CLINICAL TRIAL BUILD WITH NEW CLOUD CLINICAL MDRSUITE
Share
X
Formedix Expedites Clinical Trial Build with New Cloud Clinical MDRSuite
https://pharmaphorum.com/partner-content/formedix-expedites-clinical-trial-build-with-new-cloud-clinical-mdr-suite/See all
APPOINTMENTS
PRESCIENT HEALTHCARE GROUP TO PARTNER WITH BRIDGEPOINT DEVELOPMENTCAPITAL
Share
X
Prescient Healthcare Group to Partner with Bridgepoint DevelopmentCapital
https://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/ PRESCIENT ANNOUNCES RECENT APPOINTMENTS TO ITS SENIOR TEAMShare
X
Prescient Announces Recent Appointments to its Senior Team https://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-its-senior-team/See all
GET IN-DEPTH NEWS, OPINIONS AND FEATURES ON PHARMA AND HEALTHCARE SENT STRAIGHT TO YOUR INBOXFEATURED CONTENT
HOW TO IMPROVE PAYER ENGAGEMENT WITH TAILORED VALUE COMMUNICATION HOW WILL NICE FARE IN A POST-BREXIT WORLD? HOW TO IMPROVE PAYER ENGAGEMENT WITH TAILORED VALUE COMMUNICATION HOW WILL NICE FARE IN A POST-BREXIT WORLD? HOW TO IMPROVE PAYER ENGAGEMENT WITH TAILORED VALUE COMMUNICATION HOW WILL NICE FARE IN A POST-BREXIT WORLD?previousnext
EVENTS
previousnext
__ Post an event
See all
MOST POPULAR
* Most Viewed
* Novo Nordisk crowns cell therapy pipeline with $598m Heartseed deal * After FDA approval, Alkermes plans soft launch for antipsychoticLybalvi
* NICE 'no' to Roche's risdiplam for SMA not unexpected, says patientgroup
* Sanofi's venglustat bombs again, but isn't dead yet * UK is talking to AstraZeneca about beta variant COVID jabSee all
TWEETS FROM @PHARMAPHORUMBack to Top
* Advertise
* pharmaphorum connect* Contribute
* Work for pharmaphorum* About us
* Contact us
* Privacy policy
* Terms & conditions* Cookie Policy
* __
* __
* __
* __
* __
The rights of trade mark owners are acknowledged. pharmaphorum medialimited
Website and content copyright © 2009-2021, pharmaphorum media limited or its licensors; all rights reserved.2021
Powered by WordPress • Themify WordPressThemes
CONTINUE TO SITE >
X
Close in 10 seconds
Pharmaphorum.com
Spread the message. Stop the virus.HandsWash often
ElbowCough into
FaceDon't touch
SpaceAvoid crowds
HomeStay inside
1,511,104Confirmed 328,661RecoveredDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0